PATIENT ALERT CARD

XELJANZ®
(tofacitinib citrate)

Version: XELJ-MT-EM-V2.0
Date of approval:17 Sep 2018

PATIENT ALERT CARD

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

- This card contains important safety information that you need to be aware of before you start taking XELJANZ® and during your treatment with XELJANZ. If you do not understand this information, please ask your doctor/pharmacist to explain it to you.
- Keep this card with you and show it to any doctor or pharmacist involved in your care.
- See the XELJANZ® package leaflet for more information. You should use XELJANZ® following the package leaflet.

Tell your doctor or your pharmacist about ALL the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.

XELJANZ® is not recommended for use with biologic DMARDs for rheumatoid arthritis or psoriatic arthritis, biologics for ulcerative colitis, or with certain other medicines that depress your immune system (e.g., azathioprine, mercaptopurine, tacrolimus or cyclosporine). Taking XELJANZ® with these medicines may increase your risk of immunosuppression and infection.

During treatment with XELJANZ®

Tell your doctor immediately if you:

- Develop symptoms of an infection, such as fever, persistent cough, weight loss, or excessive tiredness. XELJANZ® may increase your risk of getting infections, which can become serious if not treated. You may be at higher risk for infections if you are 65 years of age or older, have diabetes, chronic lung disease, or are taking corticosteroids. Your XELJANZ® treatment may be stopped by your doctor.
- Develop any symptoms of herpes zoster, such as painful skin rash or blisters.
- Have been in close contact with a person with tuberculosis.

- Notice any new growth on the skin or any changes in existing moles or spots.
- Develop symptoms of interstitial lung disease, such as shortness of breath
- Develop abdominal signs and symptoms such as stomach pain, abdominal pain, blood in your stool, or any change in your bowel habits with fever.
- Develop yellow skin, nausea or vomiting.
- Are due to receive any vaccine. You should not receive certain types of vaccines while taking XELJANZ®.
- Become pregnant or plan on becoming pregnant. XELJANZ® must not be used during pregnancy. Women of childbearing potential should be advised to use effective contraception during treatment with XELJANZ® and for at least 4 weeks after the last dose.
- Women must not breast-feed while being treated with XELJANZ®.

Other Information *(please complete)*

Patient's Name: .....

Doctor's Name: .....

Doctor's Phone: .....

Doctor's Fax: .....

If you stop taking XELJANZ®, keep this card with you for at least 2 months after taking the last dose of XELJANZ®